Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743201887> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2743201887 abstract "INTRODUCTION: All-trans-retinoic acid (ATRA) and arsenic trioxide (As2O3) are clinically used in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML) characterized by translocation t(15 ; 17). Both substances have also shown some promising results on other types of AML in vitro, but those results have either been disputed by clinical trials or the tested doses were too high to be used clinically without serious toxicity. METHODS: In this study, we investigated whether addition of rapamycin, inhibitor of mTOR kinase, enhances the effects of ATRA and As2O3 on AML cell lines. Furthermore, we tested possible synergistic effect of combination of ATRA and As2O3 on given cell lines. NB4, HL60, U937, KG-1 and K562 cells were incubated with ATRA, two doses of As2O3, rapamycin and their combination. Cell proliferation was quantified by determining the number of viable cells with hemocytometer. The surface expression of CD11b was used as marker of cell differentiation and it was determined by flow cytometric analysis. The initial activity of mTOR kinase in each cell line was measured with western blot analysis of level of phosphorilated p70 S6 kinase. RESULTS: Rapamycin potentiates antiproliferative effects of lower doses of As2O3 in all non-APL AML cells without affecting their differentiation. The correlation between the initial activity of mTOR and the reactivity on As2O3 and rapamycin is not clear. Rapamycin also increased ATRA-induced differentiation of HL60 and U937 cells. Combination of ATRA and As2O3 was the most efficient in reducing cell number and inducing differentiation in cell lines tested. CONCLUSION: Our study demonstrated that combination of rapamycin and lower doses of arsenic trioxide as well as combination of all-trans-retinoic acid and arsenic trioxide may have a role in treatment of AML that lack typical t(15 ; 17) translocation." @default.
- W2743201887 created "2017-08-17" @default.
- W2743201887 creator A5001493531 @default.
- W2743201887 creator A5038316031 @default.
- W2743201887 date "2011-01-01" @default.
- W2743201887 modified "2023-09-27" @default.
- W2743201887 title "Antiproliferative effects of arsenic trioxide on leukemia cells are enhanced by rapamycin and all-trans-retinoic acid" @default.
- W2743201887 hasPublicationYear "2011" @default.
- W2743201887 type Work @default.
- W2743201887 sameAs 2743201887 @default.
- W2743201887 citedByCount "0" @default.
- W2743201887 crossrefType "journal-article" @default.
- W2743201887 hasAuthorship W2743201887A5001493531 @default.
- W2743201887 hasAuthorship W2743201887A5038316031 @default.
- W2743201887 hasConcept C185592680 @default.
- W2743201887 hasConcept C190283241 @default.
- W2743201887 hasConcept C203014093 @default.
- W2743201887 hasConcept C2776601000 @default.
- W2743201887 hasConcept C2778461978 @default.
- W2743201887 hasConcept C2778729363 @default.
- W2743201887 hasConcept C2778903051 @default.
- W2743201887 hasConcept C2779982571 @default.
- W2743201887 hasConcept C2780386689 @default.
- W2743201887 hasConcept C2781121885 @default.
- W2743201887 hasConcept C502942594 @default.
- W2743201887 hasConcept C54355233 @default.
- W2743201887 hasConcept C55493867 @default.
- W2743201887 hasConcept C62112901 @default.
- W2743201887 hasConcept C81885089 @default.
- W2743201887 hasConcept C86554907 @default.
- W2743201887 hasConcept C86803240 @default.
- W2743201887 hasConcept C98274493 @default.
- W2743201887 hasConceptScore W2743201887C185592680 @default.
- W2743201887 hasConceptScore W2743201887C190283241 @default.
- W2743201887 hasConceptScore W2743201887C203014093 @default.
- W2743201887 hasConceptScore W2743201887C2776601000 @default.
- W2743201887 hasConceptScore W2743201887C2778461978 @default.
- W2743201887 hasConceptScore W2743201887C2778729363 @default.
- W2743201887 hasConceptScore W2743201887C2778903051 @default.
- W2743201887 hasConceptScore W2743201887C2779982571 @default.
- W2743201887 hasConceptScore W2743201887C2780386689 @default.
- W2743201887 hasConceptScore W2743201887C2781121885 @default.
- W2743201887 hasConceptScore W2743201887C502942594 @default.
- W2743201887 hasConceptScore W2743201887C54355233 @default.
- W2743201887 hasConceptScore W2743201887C55493867 @default.
- W2743201887 hasConceptScore W2743201887C62112901 @default.
- W2743201887 hasConceptScore W2743201887C81885089 @default.
- W2743201887 hasConceptScore W2743201887C86554907 @default.
- W2743201887 hasConceptScore W2743201887C86803240 @default.
- W2743201887 hasConceptScore W2743201887C98274493 @default.
- W2743201887 hasLocation W27432018871 @default.
- W2743201887 hasOpenAccess W2743201887 @default.
- W2743201887 hasPrimaryLocation W27432018871 @default.
- W2743201887 hasRelatedWork W1974359797 @default.
- W2743201887 hasRelatedWork W1994329064 @default.
- W2743201887 hasRelatedWork W2039805520 @default.
- W2743201887 hasRelatedWork W2086618205 @default.
- W2743201887 hasRelatedWork W2089470325 @default.
- W2743201887 hasRelatedWork W2283656211 @default.
- W2743201887 hasRelatedWork W2359690263 @default.
- W2743201887 hasRelatedWork W2373704655 @default.
- W2743201887 hasRelatedWork W2380613903 @default.
- W2743201887 hasRelatedWork W2415464599 @default.
- W2743201887 hasRelatedWork W2415979294 @default.
- W2743201887 hasRelatedWork W2431070870 @default.
- W2743201887 hasRelatedWork W2514966263 @default.
- W2743201887 hasRelatedWork W2527608009 @default.
- W2743201887 hasRelatedWork W2552184685 @default.
- W2743201887 hasRelatedWork W2555625556 @default.
- W2743201887 hasRelatedWork W2574443615 @default.
- W2743201887 hasRelatedWork W2580495053 @default.
- W2743201887 hasRelatedWork W2944074286 @default.
- W2743201887 hasRelatedWork W3012251781 @default.
- W2743201887 isParatext "false" @default.
- W2743201887 isRetracted "false" @default.
- W2743201887 magId "2743201887" @default.
- W2743201887 workType "article" @default.